Veracyte Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Veracyte stock.
View analyst ratings for Veracyte or view top-rated stocks.

Wall Street analysts have given Veracyte a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Veracyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Veracyte is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Veracyte.

Veracyte, Inc. (NASDAQ:VCYT) issued its quarterly earnings results on Thursday, July, 29th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.12. The biotechnology company had revenue of $55.11 million for the quarter, compared to analysts' expectations of $47.73 million. Veracyte had a negative trailing twelve-month return on equity of 4.05% and a negative net margin of 40.06%.
View Veracyte's earnings history.

Veracyte's stock was trading at $23.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VCYT shares have increased by 117.4% and is now trading at $51.20.
View which stocks have been most impacted by COVID-19.

Veracyte issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200 million-$208 million, compared to the consensus revenue estimate of $197.90 million.

10 Wall Street analysts have issued 12 month price targets for Veracyte's stock. Their forecasts range from $42.00 to $60.00. On average, they anticipate Veracyte's stock price to reach $53.44 in the next year. This suggests a possible upside of 4.4% from the stock's current price.
View analysts' price targets for Veracyte or view top-rated stocks among Wall Street analysts.

Some companies that are related to Veracyte include Guardant Health (GH), Natera (NTRA), Invitae (NVTA), Elekta AB (publ) (EKTAY), CareDx (CDNA), Fulgent Genetics (FLGT), Burning Rock Biotech (BNR), Castle Biosciences (CSTL), RadNet (RDNT), Genetron (GTH), DermTech (DMTK), Personalis (PSNL), Renalytix AI (RNLX), Celcuity (CELC) and Sera Prognostics (SERA).
View all of VCYT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (9.95%), BlackRock Inc. (8.99%), Vanguard Group Inc. (8.85%), Artisan Partners Limited Partnership (7.06%), Invesco Ltd. (5.99%) and William Blair Investment Management LLC (5.70%). Company insiders that own Veracyte stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Mark Ho and Robert S Epstein.
View institutional ownership trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, William Blair Investment Management LLC, Bank of New York Mellon Corp, Jennison Associates LLC, Prudential Financial Inc., Goldman Sachs Group Inc., Vanguard Group Inc., and Dimensional Fund Advisors LP. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Giulia C Kennedy, John Walter Hanna Jr, Karin Eastham, Kevin K Gordon, and Mark Ho.
View insider buying and selling activity for Veracyte or view top insider-selling stocks.

VCYT stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Champlain Investment Partners LLC, Macquarie Group Ltd., State Street Corp, Bamco Inc. NY, Artisan Partners Limited Partnership, Bank of Montreal Can, and Eagle Asset Management Inc..
View insider buying and selling activity for Veracyte or or view top insider-buying stocks.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCYT stock can currently be purchased for approximately $51.20.

Veracyte has a market capitalization of $3.63 billion and generates $117.48 million in revenue each year. The biotechnology company earns $-34,910,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis.

Veracyte employs 320 workers across the globe.

The official website for Veracyte is www.veracyte.com.

Veracyte is headquartered at 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 243-6300 or via email at [email protected].